Simmbion
Develops an implantable engineered microbial platform that provides single-injection, sustained in vivo secretion of therapeutic proteins and peptides to treat chronic and rare diseases. Platform is based on an engineered microbial chassis and genetic constructs that enable months-long production of therapeutics at steady levels, with a built-in option for reversal using antimicrobials. Lead development program targets enzyme replacement therapy for Gaucher disease; additional programs target diabetes/obesity and cancer.
Industries
Nr. of Employees
small (1-50)
Products
Implantable engineered microbial therapeutic platform
A platform comprising an engineered nonpathogenic microbial chassis loaded with genetic constructs to produce therapeutic proteins or peptides in vivo over many months after a single subcutaneous injection; designed for reversibility via antimicrobials.
SimmbionsTM
Trypanosomal symbionts implanted via a single injection for sustained secretion of specific therapeutic proteins and peptides directly into the bloodstream, spleen, gut, and lymph nodes, eliminating the need for recurrent needle-based administration.
Simmbion™
Engineered symbiotic microbes that deliver sustained-release therapeutics from a single subcutaneous injection, designed to overcome treatment failure in chronic biologic drug therapies.
Implantable engineered microbial therapeutic platform
A platform comprising an engineered nonpathogenic microbial chassis loaded with genetic constructs to produce therapeutic proteins or peptides in vivo over many months after a single subcutaneous injection; designed for reversibility via antimicrobials.
SimmbionsTM
Trypanosomal symbionts implanted via a single injection for sustained secretion of specific therapeutic proteins and peptides directly into the bloodstream, spleen, gut, and lymph nodes, eliminating the need for recurrent needle-based administration.
Simmbion™
Engineered symbiotic microbes that deliver sustained-release therapeutics from a single subcutaneous injection, designed to overcome treatment failure in chronic biologic drug therapies.
Services
Development and preclinical evaluation of engineered microbial therapeutics intended to provide long-term secretion of therapeutic proteins following a single implantation.
Development and preclinical evaluation of engineered microbial therapeutics intended to provide long-term secretion of therapeutic proteins following a single implantation.
Expertise Areas
- Cell and gene therapy
- Synthetic biology and microbial chassis engineering
- Sustained-release biologic delivery
- Rare disease therapeutic development
Key Technologies
- Engineered microbial chassis
- Genetic construct design for therapeutic expression
- Implantable living therapeutic platforms
- Sustained in vivo protein secretion
News & Updates
The company reports pending patents that cover the microbial chassis, the genetic constructs ('engine'), and the implantable therapeutic platform and their uses.
Company's lead development program is an enzyme replacement therapy program for Gaucher disease intended to replace frequent injections with a single implantation.
The company reports pending patents that cover the microbial chassis, the genetic constructs ('engine'), and the implantable therapeutic platform and their uses.
Company's lead development program is an enzyme replacement therapy program for Gaucher disease intended to replace frequent injections with a single implantation.